- Brief summary of research interests
|
Dr. Slayton's research includes a laboratory based component studying bone marrow vasculature as it affects normal megakaryocyte development and leukemogenesis. He is also involved in international clinical trials for children with acute lymphoblastic leukemia (ALL) conducted by the Children's Oncology Group (COG). He participated in the Infant Leukemia trial where he was a member of the transplant and basic science subcommittee. He also was a member of the Very High Risk Leukemia Committee which tested the role of imatinib in the treatment of Philadelphia Chromosome positive ALL. He has developed and is chairing the successor trial for Ph+ acute lymphoblastic trial using a second generation targeted tyrosine kinase inhibition (dasatinib) in combination with an intensive chemotherapy backbone. He is looking at ways of combining targeted therapies for Ph+ leukemia to reduce toxicity. |